| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study |
| Creator | Flecchia et al. |
| Author | Clémence Flecchia |
| Author | Edouard Auclin |
| Author | Emily Alouani |
| Author | Mathilde Mercier |
| Author | Antoine Hollebecque |
| Author | Anthony Turpin |
| Author | Thibault Mazard |
| Author | Simon Pernot |
| Author | Marie Dutherage |
| Author | Romain Cohen |
| Author | Christophe Borg |
| Author | Vincent Hautefeuille |
| Author | Francesco Sclafani |
| Author | Meher Ben-Abdelghani |
| Author | Thomas Aparicio |
| Author | Camille Herve |
| Author | Geraldine Perkins |
| Author | Kathrin Heinrich |
| Author | Volker Kunzmann |
| Author | Claire Gallois |
| Author | Rosine Guimbaud |
| Author | David Tougeron |
| Author | Julien Taieb |
| Abstract | BACKGROUND: The outstanding efficacy of immunotherapy in metastatic dMMR/MSI gastro-intestinal (GI) cancers has led to a rapid increase in the number of patients treated. However, 20-30% of patients experience primary resistance to immune checkpoint inhibitors (ICIPR) and need better characterization. METHODS: This AGEO real-world study retrospectively analyzed the efficacy and safety of ICIs and identified clinical variables associated with ICIPR in patients with metastatic dMMR/MSI GI cancers treated with immunotherapy between 2015 and 2022. RESULTS: 399 patients were included, 284 with colorectal cancer (CRC) and 115 with non-CRC, mostly treated by an anti-PD(L)1 (88.0%). PFS at 24 months was 55.8% (95CI [50.8-61.2]) and OS at 48 months was 59.1% (95CI [53.0-65.9]). ORR was 51.0%, and 25.1% of patients were ICIPR. There was no statistical difference in ORR, DCR, PFS, or OS between CRC and non-CRC groups. In multivariable analysis, ICIPR was associated with ECOG-PS???2 (OR?=?3.36), liver metastases (OR?=?2.19), peritoneal metastases (OR?=?2.00), ?1 previous line of treatment (OR?=?1.83), and age?50 years old (OR?=?1.76). CONCLUSION: These five clinical factors associated with primary resistance to ICIs should be considered by physicians to guide treatment choice in GI dMMR/MSI metastatic cancer patients. |
| Publication | British Journal of Cancer |
| Volume | 130 |
| Issue | 3 |
| Pages | 442-449 |
| Date | 2024-02 |
| Journal Abbr | Br J Cancer |
| Language | eng |
| DOI | 10.1038/s41416-023-02524-3 |
| ISSN | 1532-1827 |
| Short Title | Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer |
| Library Catalog | PubMed |
| Extra | PMID: 38102227 PMCID: PMC10844357 |
| Tags | Brain Neoplasms, Colorectal Neoplasms, Gastrointestinal Neoplasms, Humans, Immunotherapy, Liver Neoplasms, Microsatellite Instability, Middle Aged, Neoplastic Syndromes, Hereditary, Retrospective Studies |
| Date Added | 2024/10/07 - 16:40:09 |
| Date Modified | 2024/10/07 - 16:40:09 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
